These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 29927999)

  • 21. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
    Blanco-Aparicio C; Collazo AM; Oyarzabal J; Leal JF; Albarán MI; Lima FR; Pequeño B; Ajenjo N; Becerra M; Alfonso P; Reymundo MI; Palacios I; Mateos G; Quiñones H; Corrionero A; Carnero A; Pevarello P; Lopez AR; Fominaya J; Pastor J; Bischoff JR
    Cancer Lett; 2011 Jan; 300(2):145-53. PubMed ID: 21051136
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protein profiling identifies mTOR pathway modulation and cytostatic effects of Pim kinase inhibitor, AZD1208, in acute myeloid leukemia.
    Chen LS; Yang JY; Liang H; Cortes JE; Gandhi V
    Leuk Lymphoma; 2016 Dec; 57(12):2863-2873. PubMed ID: 27054578
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AZD1208, a Pan-Pim Kinase Inhibitor, Has Anti-Growth Effect on 93T449 Human Liposarcoma Cells via Control of the Expression and Phosphorylation of Pim-3, mTOR, 4EBP-1, S6, STAT-3 and AMPK.
    Yadav AK; Kumar V; Bailey DB; Jang BC
    Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30654529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intrinsic resistance to PIM kinase inhibition in AML through p38α-mediated feedback activation of mTOR signaling.
    Brunen D; García-Barchino MJ; Malani D; Jagalur Basheer N; Lieftink C; Beijersbergen RL; Murumägi A; Porkka K; Wolf M; Zwaan CM; Fornerod M; Kallioniemi O; Martínez-Climent JÁ; Bernards R
    Oncotarget; 2016 Jun; 7(25):37407-37419. PubMed ID: 27270648
    [TBL] [Abstract][Full Text] [Related]  

  • 25. 2-Thioxothiazolidin-4-one Analogs as Pan-PIM Kinase Inhibitors.
    Yun Y; Hong VS; Jeong S; Choo H; Kim S; Lee J
    Chem Pharm Bull (Tokyo); 2021; 69(9):854-861. PubMed ID: 34470949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
    Brault L; Gasser C; Bracher F; Huber K; Knapp S; Schwaller J
    Haematologica; 2010 Jun; 95(6):1004-15. PubMed ID: 20145274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target.
    Rout AK; Dehury B; Parida SN; Rout SS; Jena R; Kaushik N; Kaushik NK; Pradhan SK; Sahoo CR; Singh AK; Arya M; Behera BK
    Int J Biol Macromol; 2024 Jun; 270(Pt 1):132030. PubMed ID: 38704069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
    Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
    Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the Pim kinases in multiple myeloma.
    Keane NA; Reidy M; Natoni A; Raab MS; O'Dwyer M
    Blood Cancer J; 2015 Jul; 5(7):e325. PubMed ID: 26186558
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanisms of cytotoxicity to Pim kinase inhibitor, SGI-1776, in acute myeloid leukemia.
    Chen LS; Redkar S; Taverna P; Cortes JE; Gandhi V
    Blood; 2011 Jul; 118(3):693-702. PubMed ID: 21628411
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer.
    Rebello RJ; Kusnadi E; Cameron DP; Pearson HB; Lesmana A; Devlin JR; Drygin D; Clark AK; Porter L; Pedersen J; Sandhu S; Risbridger GP; Pearson RB; Hannan RD; Furic L
    Clin Cancer Res; 2016 Nov; 22(22):5539-5552. PubMed ID: 27486174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
    Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
    Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PIM-1 kinase inhibitor SMI-4a exerts antitumor effects in chronic myeloid leukemia cells by enhancing the activity of glycogen synthase kinase 3β.
    Fan RF; Lu Y; Fang ZG; Guo XY; Chen YX; Xu YC; Lei YM; Liu KF; Lin DJ; Liu LL; Liu XF
    Mol Med Rep; 2017 Oct; 16(4):4603-4612. PubMed ID: 28849186
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Insulin receptor substrate 1 is a substrate of the Pim protein kinases.
    Song JH; Padi SK; Luevano LA; Minden MD; DeAngelo DJ; Hardiman G; Ball LE; Warfel NA; Kraft AS
    Oncotarget; 2016 Apr; 7(15):20152-65. PubMed ID: 26956053
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel benzylidene-thiazolidine-2,4-diones inhibit Pim protein kinase activity and induce cell cycle arrest in leukemia and prostate cancer cells.
    Beharry Z; Zemskova M; Mahajan S; Zhang F; Ma J; Xia Z; Lilly M; Smith CD; Kraft AS
    Mol Cancer Ther; 2009 Jun; 8(6):1473-83. PubMed ID: 19509254
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
    Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
    Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanism-based combinations with Pim kinase inhibitors in cancer treatments.
    Yang Q; Chen LS; Gandhi V
    Curr Pharm Des; 2014; 20(42):6670-81. PubMed ID: 25341939
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Pim kinases: new targets for drug development.
    Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
    Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
    Martín-Sánchez E; Odqvist L; Rodríguez-Pinilla SM; Sánchez-Beato M; Roncador G; Domínguez-González B; Blanco-Aparicio C; García Collazo AM; Cantalapiedra EG; Fernández JP; Curiel del Olmo S; Pisonero H; Madureira R; Almaraz C; Mollejo M; Alves FJ; Menárguez J; González-Palacios F; Rodríguez-Peralto JL; Ortiz-Romero PL; Real FX; García JF; Bischoff JR; Piris MA
    PLoS One; 2014; 9(11):e112148. PubMed ID: 25386922
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.
    Liu Z; He W; Gao J; Luo J; Huang X; Gao C
    Oncotarget; 2015 Apr; 6(10):8019-35. PubMed ID: 25749522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.